Valuation: Positron Corporation

Market Cap 55.84M 48.82M 45.03M 41.4M 78.44M 5.37B 79.78M 538M 211M 2.63B 210M 205M 9.05B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 54.7M 47.83M 44.12M 40.56M 76.84M 5.26B 78.16M 527M 207M 2.57B 205M 201M 8.87B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%+5.01%-12.69%-21.09% 13.34B
-1.89%-13.40%+57.84%-2.40% 4.39B
+2.13%-6.60%+61.22%+100.90% 1.17B
+3.33%+3.17%-32.66%-60.63% 1.17B
+1.60%+3.85%-37.97%-46.34% 1.1B
+1.62%+3.58%-45.15% - 901M
-1.19%-12.23%+108.81%+109.54% 551M
-0.47%+11.64%+44.85% - 318M
+1.37%+3.82%-52.35%+231.87% 257M
Average +0.60%-0.47%+10.21%+44.55% 2.58B
Weighted average by Cap. -0.60%-2.09%+4.15%-7.99%

Financials

2024 2025
Net sales 588K 514K 474K 436K 825K 56.53M 839K 5.66M 2.22M 27.63M 2.21M 2.16M 95.23M 461K 403K 372K 342K 648K 44.4M 659K 4.44M 1.74M 21.7M 1.73M 1.69M 74.8M
Net income -2.38M -2.08M -1.92M -1.76M -3.34M -229M -3.4M -22.91M -8.99M -112M -8.93M -8.74M -386M -10.6M -9.27M -8.55M -7.86M -14.9M -1.02B -15.15M -102M -40.06M -499M -39.82M -38.95M -1.72B
Net Debt 1.42M 1.25M 1.15M 1.06M 2M 137M 2.04M 13.72M 5.38M 66.99M 5.35M 5.23M 231M -1.14M -993K -916K -842K -1.6M -109M -1.62M -10.94M -4.29M -53.43M -4.27M -4.17M -184M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-